嘉峻 涂

Mr. 嘉峻 涂

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
YHYu-Ting Hsieh
Yu-Ting Hsieh
TTTsung-Lin Tsai
Tsung-Lin Tsai
嘉涂嘉峻 涂
嘉峻 涂
SHShen-Yan Huang
Shen-Yan Huang
JHJian-Wen Heng
Jian-Wen Heng
CHChia-Lin Hsu
Chia-Lin Hsu
An increasing body of evidence emphasizes the role of metabolic reprogramming in immune cells to fight off infections. However, little is known about the regulation of metabolite transporters that facilitate and support metabolic demands. In this study, we found that equilibrative nucleoside transporter 3 (ENT3) expression is part of the innate immune response, and is rapidly upregulated upon bacterial and viral infection. The transcription of ENT3 is directly under the regulation of IFN-induced signaling, positioning this metabolite transporter as an Interferon-stimulated gene (ISG). Moreover, we unveil that several viruses, including SARS-CoV2, require ENT3 to facilitate their entry into the cytoplasm. The removal or suppression of ENT3 expression is sufficient to significantly decrease viral replication in vitro and in vivo.

17 December 2025 in Diseases
Verified
Journal Article
Open access
PDF file
Cheng-Yu ChangCheng-Yu Chang
Cheng-Yu Chang
嘉涂嘉峻 涂
嘉峻 涂
SLShian-Ren Lin
Shian-Ren Lin
CFChih-Hao Fang
Chih-Hao Fang
PTPo-Wei Tseng
Po-Wei Tseng
ALand Jan-Mou Lee
and Jan-Mou Lee
Background: Patients with EGFR-mutated non-small cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase inhibitors (TKIs), but current EGFR mutation profiling relies on invasive tumor biopsies. Developing less invasive approaches, particularly proteomic evaluation of circulating tumor cells (CTCs) for EGFR mutation profiling, remains crucial. Methods: A flow cytometry method for detecting EGFRL858R-bearing CTCs was established by spiking NCI-H1975 cells into blood from cancer-naive donors. The method was then applied to blood samples from 21 NSCLC patients and 10 cancer-naive donors. Results: The gating strategy was defined by CD45−CK-7/8+CK-14/15/16/19−EpCAM+vimentin+EGFRL858R, with a cut-off value of 5 cells/mL. The method yielded positive results in all seven patients with the EGFRL858R mutation and negative results in all ten cancer-naive donors. Compared to the PCR-based reference method, the approach showed 100% positive and 71% negative agreement. Crucially, our in-house method detected EGFRL858R-bearing CTCs in three patients initially identified as EGFR wild-type and one patient with a different EGFR mutation. The remaining samples were concordant with PCR. Notably, two patients with these discordant results received EGFR-TKIs and experienced partial responses. Conclusions: This study introduces a feasible, less invasive proteomic approach for binarily detecting EGFR mutations in CTCs, offering a novel means for patient identification.